MiNK Therapeutics develops allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases, utilizing a dual-mechanism approach that combines the cytotoxicity of natural killer cells with the memory response of T cells. Their off-the-shelf therapy, which does not require lymphodepletion or HLA matching, aims to improve patient outcomes in solid tumors and acute respiratory distress syndrome.
Funding
Funding not disclosed
NIFounders
Product
Problem
Current cancer and immune-mediated disease treatments often fail to elicit durable responses due to limitations in targeting and immune activation. Traditional therapies may not effectively distinguish between healthy and diseased cells, leading to off-target effects and limited efficacy. Furthermore, many existing immunotherapies require patient-specific customization or pre-conditioning regimens that can be complex and carry significant risks.
Solution
MiNK Therapeutics is developing allogeneic invariant natural killer T (iNKT) cell therapies designed to overcome these limitations by leveraging the unique properties of iNKT cells. Their off-the-shelf approach utilizes iNKT cells that can recognize and eliminate cancer cells while also modulating the immune system to promote a sustained anti-tumor response. MiNK's iNKT cell therapies are designed to be administered without the need for lymphodepletion or HLA matching, potentially improving patient access and reducing treatment-related toxicities. The company is also engineering iNKT cells with precision targeting capabilities, such as CAR constructs and bispecific engagers, to enhance their specificity and potency against various cancer types. This dual-mechanism approach, combining innate cytotoxicity with adaptive immune memory, aims to provide more effective and accessible treatments for both solid tumors and immune-mediated diseases.
Target Audience
The primary target audience includes patients with solid tumors and immune-mediated diseases, as well as healthcare providers seeking more effective and accessible cell-based immunotherapies.
Features
- Allogeneic, off-the-shelf iNKT cell therapy platform for rapid deployment and scalability
- Dual mechanism of action: direct tumor cell killing and immune system modulation
- Engineered iNKT cells with CAR constructs (e.g., FAP-CAR-iNKT, BCMA-CAR-iNKT) for enhanced tumor targeting
- Bispecific iNKT cell engagers to redirect iNKT cell activity to specific tumor antigens
- AGENT-797: Lead product candidate in Phase 1 clinical trials for solid tumors and acute respiratory distress syndrome (ARDS)
- No requirement for lymphodepletion or HLA matching, simplifying treatment administration
- Next-generation technology platform for developing novel engineered iNKT cell therapies